Hybrid branded drugs approved through the US 505(b)(2) regulatory pathway, as well as biosimilars, will be at the forefront of Amneal’s attempts to restore growth by focusing on higher-value, less-competitive opportunities, according to the US firm’s co-founder Chintu Patel, who has just regained control of the company’s direction, along with his older brother Chirag.
Amneal Will Go After 505(b)(2) Opportunity Under Patels’ Leadership
Capitalizing on opportunities in the US hybrid 505(b)(2) market will be central to Amneal’s strategy to revive its fortunes now its founders, brothers Chirag and Chintu Patel, have again taken the helm.
